Efficacy of Paclitaxel plus TS1 against previously treated EGFR mutated non-small cell lung cancer.

ABSTRACT:

Background

Later line chemotherapy (≥2nd lines) such as Docetaxel or immunotherapy is frequently used. As the life expectancy of lung cancer patients is getting longer, we need to provide more treatment options. Other treatment options are not well documented except for Doxetaxel and immunotherapy. Therefore, the efficacy of paclitaxel plus TS1 (TTS1) is warranted.

Methods

We retrospectively reviewed the chart records of our non-small cell lung cancer patients who were treated between 2010 and 2013. Clinical characteristics, type of tumor, EGFR mutation status, and treatment response to first-line EGFR-TKI therapy and efficacy of TTS1, were collected.

Results

Twenty eight patients were enrolled in this study. No patients archived complete response and seven patients h

SUBMITTER: Tseng YH 

PROVIDER: S-EPMC6764356 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature